Ratings EBOS Group Limited

Equities

EBO

NZEBOE0001S6

End-of-day quote New Zealand S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
34.3 ^NZD	-3.24%		-1.12%	-3.38%

04-26	New Zealand Shares Drop on Consumer Pessimism; Ebos Group Falls 3% After Appointing New CFO	MT
04-25	Ebos Group Appoints New CFO	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.56 for the 2024 fiscal year.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company does not generate enough profits, which is an alarming weak point.
The firm trades with high earnings multiples: 21.4 times its 2024 earnings per share.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
EBOS GROUP LIMITED	-3.38%	3.93B	B-
MCKESSON CORPORATION	+17.35%	71.39B	C+
CARDINAL HEALTH, INC.	+2.39%	25.1B	C+
SINOPHARM GROUP CO. LTD.	+5.38%	8.59B	C
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.69%	8.19B	B
HUADONG MEDICINE CO., LTD	-20.96%	7.91B	B-
H. LUNDBECK A/S	+0.49%	4.54B	B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B	B+
GALENICA AG	-2.61%	3.86B	B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+22.08%	3.64B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes